Here are the 424B prospectus supplements from Kodiak Sciences Inc (KOD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KOD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOD filings page.
Kodiak Sciences Inc. is conducting a primary offering of 6,956,522 shares of common stock at $23.00 per share, raising estimated net proceeds of about $149.9 million after underwriting discounts and expenses. Underwriters also have a 30‑day option to buy up to 1,043,478 additional shares. Kodiak expects 59,955,083 shares outstanding after the offering, or 60,998,561 shares if the option is fully exercised, compared with 52,998,561 shares as of September 30, 2025.
The company plans to use the cash, together with existing funds, for working capital and general corporate purposes as it advances three late‑stage retinal drug candidates (KSI‑101, KSI‑501 and tarcocimab) across multiple Phase 3 trials, with several topline readouts expected between 2026 and 2027. At the $23.00 offering price, new investors face immediate net tangible book value dilution of $20.10 per share, as adjusted book value would rise from $0.45 to $2.90 per share. Entities affiliated with Baker Bros. Advisors and director Dr. Felix J. Baker have indicated interest in purchasing up to one‑third of the offered shares, though this indication is not binding.
Kodiak Sciences Inc. is offering 6,000,000 shares of its common stock in an underwritten public transaction, and has granted the underwriters a 30-day option to purchase up to 900,000 additional shares. Based on 52,998,561 shares outstanding as of September 30, 2025, Kodiak expects to have 58,998,561 shares outstanding after the offering, or 59,898,561 shares if the option is exercised in full.
The company plans to use the net proceeds, together with current cash and cash equivalents, for working capital and general corporate purposes. Entities affiliated with Baker Bros. Advisors LP and director Dr. Felix J. Baker have indicated interest in purchasing up to an aggregate of one-third of the shares at the public offering price, although these indications are not binding. Kodiak is a precommercial retina-focused biotechnology company developing late-stage investigational therapies KSI-101, KSI-501 and tarcocimab across multiple Phase 3 trials, with key topline data expected between 2026 and 2027.
Investors in this offering face a high degree of risk, including immediate dilution in net tangible book value, the possibility of future equity offerings, and the company’s stated intention not to pay cash dividends, meaning potential returns would rely on stock price appreciation.